Moghaddam Davood Dorostkar, Ghadirian E, Azami M
Department of Parasitology and Mycology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Parasitol Res. 2005 Jun;96(4):273-5. doi: 10.1007/s00436-005-1363-1. Epub 2005 May 25.
Blastocystis hominis is commonly found in the intestinal tract of humans. Although the pathogenicity of this unicellular parasite is controversial, anti-protozoan agents are usually administered to infected individuals. At present, the first choice of chemotherapeutic agent is Metronidazole as described in the literature. In this study, we evaluated the effects of metronidazole and Trimethoprim/Sulfamethoxazole (TMP/SMX) on persons infected with B.hominis. A total of 104 subjects infected with B. hominis were admitted to the laboratory from 2002 to 2003. All individuals were non-immunocompromised and subjects were monitored for 1 year after treatment. All stool samples were microscopically examined after staining with iodine and by culturing in an egg slant medium. Of the 104 infected individuals (52+/-16 years of age, M:F=60:44) with B. hominis infection, 28 were discharging large numbers of parasites before treatment. Of 28 severely infected individuals, 12 were treated with metronidazole/250-750 mg at a regimen of 3 x/day/10 days and 4 of the 12 were eradicated. Nine individuals were treated with TMP/SMX/1 tab at a regimen of 3 x/day/10 days and 2 of the 9 were eradicated. For severe B. hominis infections, it appears that metronidazole and TMP/SMX are effective in some individuals, but not all.
人芽囊原虫常见于人类肠道中。尽管这种单细胞寄生虫的致病性存在争议，但通常会给感染者使用抗原虫药物。目前，如文献所述，化疗药物的首选是甲硝唑。在本研究中，我们评估了甲硝唑和甲氧苄啶/磺胺甲恶唑（TMP/SMX）对感染人芽囊原虫的人的影响。2002年至2003年，共有104名感染人芽囊原虫的受试者进入实验室。所有个体均无免疫功能低下，治疗后对受试者进行了1年的监测。所有粪便样本在碘染色后进行显微镜检查，并在鸡蛋斜面培养基中培养。在104名感染人芽囊原虫的个体（年龄52±16岁，男:女 = 60:44）中，28人在治疗前排出大量寄生虫。在28名重度感染个体中，12人接受了甲硝唑/250 - 750毫克治疗，疗程为每日3次，共10天，其中4人被根除。9人接受了TMP/SMX/1片治疗，疗程为每日3次，共10天，其中2人被根除。对于严重的人芽囊原虫感染，甲硝唑和TMP/SMX似乎对一些个体有效，但并非对所有个体都有效。
